Could a stronger dose of fulvestrant tame metastatic breast cancer?

NCT ID NCT00585507

First seen May 27, 2026 · Last updated Jun 12, 2026 · Updated 4 times

Summary

This study tests a higher dose of the drug fulvestrant (Faslodex) as a first treatment for postmenopausal women with a type of advanced breast cancer that is fueled by hormones. The goal is to see if the higher dose works better than the standard dose at controlling the cancer. About 40 women will take part, and the study will track how well the cancer responds and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02115, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Lowell General Hospital

    Lowell, Massachusetts, 01854, United States

  • Massachusetts General Hosptial

    Boston, Massachusetts, 02114, United States

  • South Shore Hospital

    South Weymouth, Massachusetts, 02190, United States

Conditions

Explore the condition pages connected to this study.